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Abstract 
Objective: To compare the efficacy of oral dydrogesterone vs intramuscular progesterone in terms of the mean 
duration of bleeding cessation in women with threatened abortion. 
Methodology: In this Randomized Controlled Trial, 552 patients diagnosed as threatened miscarriage were 
enrolled per inclusion and exclusion criteria and randomly assigned to two groups. Group A received oral 
dydrogesterone 40 mg p/o stat and then 10 mg p/o twice daily. Group B received intramuscular progesterone 
250 mg once a week. Treatment was continued until one week after bleeding stops. Patients were followed up by 
weekly visits and ultrasound was done on each visit to check the viability of a fetus. The duration of cessation of 
vaginal bleeding in days was calculated for each woman taking the first day of treatment as day 1. Data were 
analyzed using SPSS version 22. For categorical variables like gravidity, cessation of bleeding, frequencies along 
with percentages were calculated. For continuous variables like age of patient, gestational age, duration in days 
till bleeding stops, mean along with standard deviation was calculated. To compare the mean duration of 
bleeding cessation in both groups, an independent sample t-test was applied and p-value <0.05 was considered 
statistically significant.  
Results: The mean age of the patients in the study was 28.40+2.96 years. The means for gestational age and parity 
were 8.86+1.31 weeks and 0.87+0.97 respectively, whereas the mean duration of cessation of bleeding was 
8.12+1.41 days. The mean duration of cessation of bleeding in both the groups was 7.01+0.91 and 9.22+0.83 days 
respectively which was statistically significant (p-value 0.001). 
Conclusion: The study concludes that the mean duration of bleeding cessation in days was less in oral as 
compared to intramuscular progesterone group in women with threatened abortion. 
Keywords: Threatened abortion, miscarriage, Vaginal bleeding, Progesterone. 
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Introduction 
 
Miscarriage is defined as loss of pregnancy before 20 
weeks of gestation calculated from the last menstrual 
period if remembered or early dating scan1. It is one of 
the common complications that occur in 15 to 20% of 
clinically recognized pregnancies.1, 2 
Threatened miscarriage is manifested clinically by 
symptoms of vaginal bleeding, with or without 
abdominal pain but a fetus is viable (CRL 
corresponding to gestational age, cardiac activity 
positive) inside the uterine cavity and the cervix is 
closed.3,4 Threatened abortion occurs in 15 to 20% of 
pregnancies and about 50% of this progress to an 
actual abortion.5,6,7 Pathology of threatened abortion is 
multifactorial, it may occur due to chromosomal 
abnormality (50% cases), increased maternal age, 
maternal infections and maternal endocrine 
abnormalities such as diabetes, thyroid dysfunction, 
maternal use of alcohol, tobacco, polycystic ovarian 
syndrome or corpus luteum defect leading to 
insufficient endogenous progesterone.8,9 
Progesterone is an essential steroid hormone for the 
continuation of pregnancy, initially produced by 
corpus luteum (12 ± 2 days) and later placenta (7th-9th 
week of gestation).1 Progesterone prepares the 
endometrium for implantation by inducing secretory 
changes. Both progesterone and dydrogesterone 
inhibit the activity of natural killer cells at feto-
maternal interface10. Progesterone maintains uterine 
quiescence thus suppressing uterine contractions.4,11 In 
luteal phase defect, endogenous progesterone level is 
low that may lead to miscarriage.10 As progesterone 
has documented physiological role in the maintenance 
of pregnancy, it has been used for the treatment of 
threatened abortion since many years.12 
There are three routes by which progesterone can be 
given oral, vaginal and intramuscular. The preferred 
method is intramuscular.3 It provides optimal blood 
level of hormone but may cause a severe allergic 
reaction, injection site reactions like pain, swelling and 
induration.10  In contrast, oral progesterone 
(dydrogesterone) is a semi-synthetic 6-
dehydroretroisomer that is structurally and 
pharmacologically similar to endogenous 
progesterone.12 It has high selectivity for the 
progesterone receptors. 
Research has shown that the mean duration of 
treatment that is the time period during which 
bleeding stops with the viable fetus is less in patients 
taking oral dydrogesterone when compared to 
intramuscular progesterone. Hence provides adequate 
hormonal support and increases chances of successful 
pregnancy in a shorter duration of time.3 
Overall there is adequate research done on the efficacy 
of oral and intramuscular progesterone but studies on 
comparison in terms of duration of treatment with 
oral/intramuscular progesterone are few. Comparison 
of efficacy of oral dydrogesterone and intramuscular 
progesterone in terms of duration of cessation of 
vaginal bleeding in women with threatened abortion is 
important so that a better treatment option can be 
given to patients and patient’s discomfort, morbidity 
and pregnancy loss can be decreased in a shorter 
duration of time. 
 
Patients and Methods 
 
This Randomized Controlled Trial was conducted in 
the Department of Obstetrics and Gynaecology, 
District Headquarters Teaching Hospital Rawalpindi, 
over a period of six months from January 2017 to June 
2017. 552 patients (276 in each group) were enrolled in 
the study. Pregnant women of 25-40 years of age with 
less than 12 weeks of gestation, having vaginal 
bleeding, closed cervix and ultrasound evidence of a 
viable pregnancy were included in the study. While 
the women with non-viable fetuses, cervical 
incompetence and having bleeding due to low lying 
placenta were excluded from the study. All women 
fulfilling selection criteria were explained the purpose 
and procedure of study and verbal consent were 
taken. 
Selected women were randomly distributed either in 
two groups. Group A received oral dydrogesterone 40 
mg p/o stat and then 10 mg p/o twice daily. Group B 
received intramuscular progesterone 250 mg once a 
week. Treatment was continued until one week after 
bleeding stops. Patients were followed up by weekly 
visits and ultrasound was done on each visit to check 
the viability of a fetus. The duration of cessation of 
vaginal bleeding in days was calculated for each 
woman taking the first day of treatment as day 1. All 
data were collected on specified proforma.  
Data was entered and analyzed using SPSS Version 22. 
For all categorical variables like primi /multigravida, 
the bleeding stopped or not, frequencies along with 
percentages were calculated. For continuous variables 
like age of patient, gravidity, parity, gestational age in 
weeks, duration in days till bleeding stops, mean along 
with standard deviation was calculated. To compare 
the mean duration of bleeding cessation in both study 
groups, an independent samples t-test was applied. A 
p-value of less than 0.05 was considered statistically 
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significant. Effect modifiers like age, parity, gestational 
age were controlled by stratification. Post-stratification 
interpretation sample t-test was applied and P-value 
<0.05 was considered significant. 
 
Results 
 
The total number of patients in this study was 552. 
They were divided into two groups with 276 patients 
in each group. 
The descriptive statistics of age, parity and gestational 
age of patients were calculated in terms of mean and 
standard deviation. The mean age of the participants 
in the study was 28.40+2.96 years with ranges from 25 
to 40 years (Table 01). The mean parity of all patients 
in the study was 0.87+0.97 with maximum parity of 03 
were included in the study (Table 01). The mean 
gestational age of the participants was 8.86+1.31 weeks 
with ranges from 07 to 12 weeks (Table 01). 
Primi/multigravida was also calculated in terms of 
frequency and percentage of female patients. There 
were 258 (46.7%) primigravidas and 294 (53.3%) 
multigravidas who were included in the study 
according to the inclusion criteria. 
The objective of the study was to compare the efficacy 
of oral dydrogesterone with intramuscular 
progesterone in terms of the mean duration of 
bleeding cessation in women with threatened abortion. 
In the study, the mean duration of cessation of 
bleeding in both groups was 7.01+0.91 days and 
9.22+0.83 days respectively. Independent sample t-test 
was used to compare mean duration (days) of 
cessation of bleeding in both groups which was 
statistically significant (p-value 0.000) (Table 02). 
Effect modifier like age, gestational age, and parity of 
the patients was stratified and compared with mean 
duration (days) of cessation of bleeding in both 
groups. Mean duration (days) of cessation of bleeding 
in patients having age 25 – 30 years among both 
groups was 8.04+2.94 and 9.12+3.08 respectively, 
whereas mean duration (days) of cessation of bleeding 
in patients having age 31–40 years among both the 
groups was 8.37+2.72 and 8.37+1.42 respectively 
which was statistically significant (p-value 0.017) 
(Table 03). Mean duration of cessation of bleeding in 
patients having gestational age 7–10 weeks in both 
groups was 8.10+1.94 days and 8.22+2.08 days 
respectively, whereas mean duration of cessation of 
bleeding in women having gestational age 11–12 
weeks in both the groups was 8.02+2.13 days and 
8.92+1.80 days respectively which was not statistically 
significant (p-value 0.473), (Table 03). 
Mean duration (days) of cessation of bleeding in 
women with threatened bleeding having parity 0–1 
was 8.00+1.94 and 8.44+2.06 respectively in both 
groups whereas mean duration (days) of cessation of 
bleeding in women having parity 2-3 among both the 
groups was 9.26+2.13 and 9.06+1.30 respectively 
which was found to be statistically significant (p-value 
0.001) (Table 03). 
 
Table 01: Baseline Characteristics 
Category Minimum 
(n=552) 
Maximum 
(n=552) 
Mean SD 
Age 
(years) 
25 40 28.40 2.96 
Parity 0 3 0.87 0.97 
Gestation
al Age 
(wks) 
7.0 12.0 8.86 1.31 
 
 
Table 02: Comparison of Mean Duration (days) of 
Cessation of Blessing in both the Groups 
Group Mean Standard 
Deviation 
P-Value 
Group A 
(n=276) 
7.01 0.91 
0.001 Group B 
(n=276) 
9.22 0.83 
 
 
Table 03: Effect modifier like Age, Gestational Age 
& Parity stratification with Duration (days) of 
Cessation of Bleeding in both the groups 
Category 
 Group A 
(n-276) 
Group B 
(n=276) 
P-
Value 
Age 
(years) 
 
25-30 
Years 
8.04+2.94 9.12+3.08 
0.017 
31 - 40 
years 
8.37+2.72 8.37+1.42 
Gestation
al Age 
(Weeks) 
7 – 10 
wks 
8.10+1.94 8.22+2.08 
0.473 
11 – 12 
wks 
8.02+2.13 8.92+1.80  
Parity 
0-1 8.00+1.94 8.44+2.06  
0.001 
2-3 
9.26+2.13 9.06+1.30 
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Discussion 
 
Threatened abortion is a common condition occurring 
in 20% of all pregnancies3. The clinical manifestations 
are as follows: vaginal bleeding, with or without lower 
abdominal pain, non-dilatation of the cervix and a 
viable fetus. The condition may lead to miscarriage in 
approximately one-half of the cases or may resolve. It 
is likely to land into complete or incomplete abortion, 
in particular during the first three months of 
pregnancy.13, 14 
The main reasons for vaginal bleeding in early 
pregnancy are subchorionic hemorrhage, subchorionic 
hematoma, and rupture of a marginal placental sinus. 
In the majority of the cases of threatened abortion, the 
bleeding is of unknown origin and usually slight. Most 
of these pregnancies continue to term with or without 
treatment. The symptoms and signs of threatened 
abortion are so variable that the outcome of the 
pregnancy cannot be reliably predicted by clinical 
features at presentation. Thus, various biochemical 
and biophysical tests have been applied extensively in 
attempts to improve the accuracy of predicting the 
outcome of these pregnancies.15 
There are several causes for threatened abortion, about 
20% are caused by endocrine factors and the rest of the 
causes involve chromosomal, genetic, anatomical, 
immunological, hormonal, infectious and 
psychological factors.14 
Progesterone is the main product of the corpus 
luteum. It increases vascularity of the endometrial 
lining and stabilizes the endometrium in the 
preparation of embryo implantation.16 Progesterone 
can be given orally, vaginally, or through 
intramuscular(IM) injection.17 Vaginal administration 
results in higher uterine concentrations but is often not 
feasible if the bleeding is severe.18 Oral administration 
is generally the easiest and most acceptable route for 
the patient.19 Research shows that dydrogesterone is 
associated with a higher rate of pregnancy and even 
lower pregnancy complications such as fetal distress 
and gestational hypertension.20 Most importantly 
intramuscular injection is painful so patient’s 
compliance is poor. 
Several studies have shown that treatment with 
dydrogesterone has led to a reduction in pregnancy 
loss in patients with threatened abortion. A study 
conducted by Omar et al. concluded that the 
pregnancy success rate was 95.9% in women given 
oral dydrogesterone as compared to 86.3% in women 
given conservative treatment.21 A study conducted on 
women presented with the sub-chorionic hemorrhage 
who were given oral dydrogesterone 40mg per day 
showed a 37% reduction in miscarriage rate.22  
In our study, the mean duration (days) of cessation of 
bleeding in women treated with oral dydrogesterone 
was less as compared to the patients treated with 
intramuscular progesterone. This finding of our study 
is similar to another study conducted by Qing G et al., 
which also showed that the success rates of fetal 
protection were 88.4% with oral dydrogesterone and 
84.9% with intramuscular progesterone.3 A review of 
the use of dydrogesterone during pregnancy showed 
no evidence of increased risk of congenital 
abnormalities in fetus.23 
Different studies have shown that oral dydrogesterone 
can effectively reduce the incidence of threatened 
abortion. It is convenient to take orally, having good 
compliance and no proven adverse reactions. 
 
Conclusion 
 
The mean duration of cessation of bleeding is less in 
women treated with oral dydrogesterone as compared 
to the patients treated with intramuscular 
progesterone. Oral dydrogesterone is also better in 
terms of convenience of administration and patient 
compliance. 
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